After working in drug discovery and development in the pharmaceutical industry, Ana Mingorance founded Dracaena in 2014 to help drug developers and rare disease foundations develop new orphan drugs for rare neurological diseases.

Ana is currently is the Chief Development Officer of the Loulou Foundation, the Scientific Director of the Dravet Syndrome Foundation Spain, and an independent consultant in genetic epilepsy syndromes and orphan drug development through Dracaena. 

For more information about Ana visit the website anamingorance.com or click on the image.